GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » Enterprise Value

Panacea Acquisition II (Panacea Acquisition II) Enterprise Value : $241.03 Mil (As of May. 22, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Panacea Acquisition II's Enterprise Value is $241.03 Mil. Panacea Acquisition II's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98 Mil. Therefore, Panacea Acquisition II's EV-to-EBIT ratio for today is -247.21.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Panacea Acquisition II's Enterprise Value is $241.03 Mil. Panacea Acquisition II's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.98 Mil. Therefore, Panacea Acquisition II's EV-to-EBITDA ratio for today is -247.21.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Panacea Acquisition II's Enterprise Value is $241.03 Mil. Panacea Acquisition II's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil. Therefore, Panacea Acquisition II's EV-to-Revenue ratio for today is .


Panacea Acquisition II Enterprise Value Historical Data

The historical data trend for Panacea Acquisition II's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II Enterprise Value Chart

Panacea Acquisition II Annual Data
Trend Dec21 Dec22
Enterprise Value
228.03 236.56

Panacea Acquisition II Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Enterprise Value Get a 7-Day Free Trial 228.03 229.28 229.67 230.64 236.56

Competitive Comparison of Panacea Acquisition II's Enterprise Value

For the Shell Companies subindustry, Panacea Acquisition II's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panacea Acquisition II's Enterprise Value Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Panacea Acquisition II's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Panacea Acquisition II's Enterprise Value falls into.



Panacea Acquisition II Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Panacea Acquisition II's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

Panacea Acquisition II's Enterprise Value for the quarter that ended in Dec. 2022 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II  (NAS:PANA) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Panacea Acquisition II's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=241.031/-0.975
=-247.21

Panacea Acquisition II's current Enterprise Value is $241.03 Mil.
Panacea Acquisition II's EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Panacea Acquisition II's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=241.031/-0.975
=-247.21

Panacea Acquisition II's current Enterprise Value is $241.03 Mil.
Panacea Acquisition II's EBITDA for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Panacea Acquisition II's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=241.031/0
=

Panacea Acquisition II's current Enterprise Value is $241.03 Mil.
Panacea Acquisition II's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Panacea Acquisition II Enterprise Value Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Panacea Acquisition II (Panacea Acquisition II) Business Description

Traded in Other Exchanges
N/A
Address
357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103
Website
Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
Executives
Ecor1 Capital Fund Qualified, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p. director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp director, 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc director, 10 percent owner 1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc director, 10 percent owner 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano director C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson director C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni director C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott director, officer: Secretary C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen officer: Chief Financial Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout officer: Chief Investment Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon officer: Chief Operating Officer C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103

Panacea Acquisition II (Panacea Acquisition II) Headlines